Dravet Syndrome Clinical Trial
Official title:
A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), Followed by a Randomized, Double-blind, Placebo-controlled Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of ZX008 as Adjunctive Antiepileptic Therapy to Stiripentol Treatment in Children and Young Adults With Dravet Syndrome (Cohort 2)
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of ZX008 (fenfluramine hydrochloride) when added to adjunctive antiepileptic stiripentol treatment in children and young adults with Dravet syndrome.
This is a multicenter, 2-cohort trial to first assess the pharmacokinetic and safety profile of a single dose of ZX008 (fenfluramine hydrochloride) oral solution when added to a standard Dravet syndrome treatment regimen containing valproate (VPA) and clobazam (CLB), with or without stiripentol (STP) (Cohort 1), followed by a randomized, double-blind, placebo-controlled parallel group evaluation of the efficacy, safety, and tolerability of ZX008 as adjunctive therapy for seizures in children and young adults with Dravet syndrome (Cohort 2). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05651204 -
GABA Biomarkers in Dravet Syndrome
|
||
| Withdrawn |
NCT02910297 -
The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
|
||
| Recruiting |
NCT04462770 -
EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome
|
Phase 2 | |
| Completed |
NCT02896608 -
Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome
|
||
| Withdrawn |
NCT05140122 -
LEONIDaS Caregivers Study
|
||
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT02091206 -
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
|
Phase 2 | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Recruiting |
NCT05472389 -
Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome
|
N/A | |
| Active, not recruiting |
NCT05626634 -
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
|
Phase 2 | |
| Recruiting |
NCT01858285 -
Genetics of Epilepsy and Related Disorders
|
||
| Recruiting |
NCT04614506 -
Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome
|
||
| Recruiting |
NCT06118255 -
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
|
Phase 3 | |
| Recruiting |
NCT04611438 -
Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome
|
Phase 3 | |
| Completed |
NCT02091375 -
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
|
Phase 3 | |
| Completed |
NCT05364021 -
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06112275 -
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03254680 -
Turmeric as Treatment in Epilepsy
|
N/A | |
| Withdrawn |
NCT02174094 -
Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
|
Phase 3 | |
| Terminated |
NCT02187809 -
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
|
Phase 3 |